ClinicalTrials.gg
CompletedNCT03038880STAIRWAYUpdated Jan 5, 2021Results posted

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

A Phase 2 interventional study of Faricimab and Ranibizumab in Neovascularization, Choroidal and Macular Degeneration, Age-Related, sponsored by Hoffmann-La Roche. Completed at 25 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Choroidal Neovascularization with a site in United States — 2 open to participants now, 9 under way, 4 of them phase 3. Choroidal Neovascularization · United States.

Enrollment
29th of 77
76 · median 42
Started
2017
with 2 others
Phase 2
23 of 88
none open now
Registered
74th of 88
by date

Among the 88 studies in Choroidal Neovascularization with a site in United States, this one is the 29th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2017, is one of 23 in phase 2, and was the 74th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

2 of the 88 studies in Choroidal Neovascularization with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Choroidal Neovascularization with a site in United States, or all of them as a file.
02

Study summary

This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.

03

Conditions studied

  • Neovascularization, Choroidal
  • Macular Degeneration, Age-Related
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naive CNV secondary to AMD (nAMD)
  • Subfoveal or juxtafoveal CNV with a subfoveal component related to the CNV activity by fundus fluorescein angiography (FFA) or spectral-domain optical coherence tomography (SD-OCT; as evidenced by subretinal fluid, subretinal hyperreflective material, evidence of leakage, or hemorrhage)
  • CNV lesion of all types with: total lesion size (including blood, atrophy, fibrosis, and neovascularization) of 6 disc areas or less by FFA; and CNV component area of at least 50% of total lesion size by FFA; and active CNV confirmed by FFA (evidence of leakage); and CNV exudation confirmed by SD-OCT (presence of fluid)
  • BCVA letter score of 73 to 24 letters (inclusive) on ETDRS-like charts (20/40-20/320 Snellen equivalent) on day 1
  • Clear ocular media and adequate pupillary dilatation to allow acquisition of good-quality retinal images to confirm diagnosis

Exclusion criteria

Exclusion Criteria:

  • CNV due to causes other than AMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis
  • Central serous chorioretinopathy at screening
  • Retinal pigment epithelial tear involving the macula
  • On FFA: subretinal hemorrhage, fibrosis, or atrophy of more than (>)50% of the total lesion area and/or that involves the fovea
  • Any prior or concomitant treatment for CNV including (but not restricted to) IVT treatment (, anti-VEGF, tissue plasminogen activator, ocriplasmin, C3F8 gas, air), periocular pharmacological intervention, argon laser photocoagulation, verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or surgical intervention
  • Cataract surgery within 3 months of baseline assessments
  • Any other intraocular surgery (pars plana vitrectomy, glaucoma surgery, corneal transplant, radiotherapy)
  • Prior IVT treatment (including anti-VEGF medication) except for management of cataract complication with steroid IVT treatment
  • Prior periocular pharmacological intervention for other retinal diseases
  • Any concurrent intraocular condition in the study eye (eg, amblyopia, aphakia, retinal detachment, cataract, diabetic retinopathy or maculopathy, or epiretinal membrane with traction) that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the course of the study
  • Active intraocular inflammation (grade trace or above) in the study eye on day 1 (before randomization)
  • Current vitreous hemorrhage in the study eye
  • Uncontrolled glaucoma (eg, progressive loss of visual fields or defined as IOP ≥25 mm Hg despite treatment with antiglaucoma medication) in the study eye
  • Spherical equivalent of refractive error demonstrating more than 8 diopters of myopia in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye on day 1 (before randomization)
  • Any major illness or major surgical procedure within 1 month before screening
  • Uncontrolled blood pressure (defined as systolic >180 mm Hg and/or diastolic >100 mm Hg while participant at rest). If a participant's initial reading exceeded these values, a second reading was taken later on the same day, or on another day during the screening period. If the participant's blood pressure was controlled by antihypertensive medication, the participant was taking the same medication continuously for at least 30 days before day 1
  • Stroke or myocardial infarction within 3 months before day 1
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory findings giving reasonable suspicion of a condition that the use of the drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator
  • Pregnant or breastfeeding, or intended to become pregnant during the study
  • Known to ranibizumab, fluorescein, any ingredients of the formulation used, dilating eye drops, or any of the anesthetic and antimicrobial drops used
  • Treatment with investigational therapy within 3 months before initiation of study treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    6 mg Faricimab Q12W

    6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).

    Drug: Faricimab · Drug: Sham Procedure

  • Experimental
    6 mg Faricimab Q16W

    6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.

    Drug: Faricimab · Drug: Sham Procedure

  • Active comparator
    0.5 mg Ranibizumab Q4W

    0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).

    Drug: Ranibizumab

Interventions

  • Faricimab was administered via IVT injections as specified during the treatment period.

    Also known as: RO6867461, RG7716

  • Ranibizumab was administered via IVT injections as specified during the treatment period.

    Also known as: Lucentis®

  • DrugSham Procedure

    The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  2. Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  3. Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  4. Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  5. Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  6. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  7. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  8. Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints

    Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  9. Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints

    Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  10. Percentage of Participants With No Intraretinal Fluid at Specified Timepoints

    The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  11. Percentage of Participants With No Subretinal Fluid at Specified Timepoints

    The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  12. Percentage of Participants With No Cysts at Specified Timepoints

    The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  13. Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints

    The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

    Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  14. Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52

    The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Baseline, Week 40, Week 52

  15. Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52

    The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Baseline, Week 40, Week 52

  16. Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52

    The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Baseline, Week 40, Week 52

  17. Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline

    Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA).

    Time frame: Predose at Baseline (Day 1), Weeks 16, 24, 28, 44, and 52

  18. Safety Summary: Number and Percentage of Participants With at Least One Adverse Event

    This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.

    Time frame: From Baseline until 28 days after the last dose of study drug (up to 52 weeks)

07

Results

Posted Jan 5, 2021
Limitations and caveats
Interpretability of the imaging endpoints is limited by the relatively small sample size of the study and imbalances between the arms at baseline. Formal comparisons could not be performed across the treatment arms.

Participant flow

Participant flow — Overall Study
Milestone6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Started243116
Completed212816
Not completed330
Withdrew: Death120
Withdrew: Physician decision210

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · ETDRS Letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts
ETDRS Letters6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts9.3 (6.4 to 12.3)12.5 (9.9 to 15.1)11.4 (7.8 to 15.0)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): -2.1 · 80% CI -6.8 to 2.6The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 1.1 · 80% CI -3.4 to 5.5The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryMean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Least squares mean · ETDRS Letters
Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts
ETDRS Letters6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 73.78 (2.33 to 5.24)4.62 (3.33 to 5.91)3.53 (1.74 to 5.33)
Week 45.99 (4.10 to 7.88)7.55 (5.88 to 9.22)7.53 (5.21 to 9.86)
Week 85.28 (2.88 to 7.69)9.15 (7.01 to 11.29)10.55 (7.55 to 13.54)
Week 127.31 (4.87 to 9.75)10.19 (8.04 to 12.34)9.91 (6.94 to 12.88)
Week 168.31 (5.93 to 10.68)11.62 (9.52 to 13.71)10.78 (7.89 to 13.68)
Week 208.02 (5.35 to 10.69)10.40 (8.05 to 12.76)11.53 (8.28 to 14.78)
Week 248.11 (5.53 to 10.69)10.37 (8.10 to 12.65)10.97 (7.83 to 14.11)
Week 289.59 (7.06 to 12.12)11.82 (9.59 to 14.05)12.16 (9.08 to 15.23)
Week 329.87 (7.21 to 12.53)12.44 (10.10 to 14.79)11.91 (8.67 to 15.14)
Week 369.01 (6.14 to 11.87)12.38 (9.86 to 14.90)12.03 (8.57 to 15.50)
Week 409.33 (6.37 to 12.29)12.47 (9.86 to 15.08)11.42 (7.83 to 15.01)
Week 449.38 (6.42 to 12.34)12.07 (9.48 to 14.67)11.22 (7.65 to 14.79)
Week 489.53 (6.51 to 12.55)10.99 (8.33 to 13.64)10.22 (6.57 to 13.86)
Week 5210.08 (7.05 to 13.12)11.42 (8.75 to 14.09)9.59 (5.93 to 13.25)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): -2.09 · 80% CI -6.75 to 2.56The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 1.05 · 80% CI -3.40 to 5.49The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 0.49 · 80% CI -4.26 to 5.25The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 1.83 · 80% CI -2.71 to 6.37The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryNumber and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Count of participants · Participants
Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 7: Gaining ≥15 Letters121
Day 7: Gaining ≥10 Letters241
Day 7: Gaining ≥5 Letters11166
Day 7: Gaining ≥0 Letters202615
Week 4: Gaining ≥15 Letters343
Week 4: Gaining ≥10 Letters585
Week 4: Gaining ≥5 Letters15198
Week 4: Gaining ≥0 Letters203015
Week 8: Gaining ≥15 Letters356
Week 8: Gaining ≥10 Letters7108
Week 8: Gaining ≥5 Letters142610
Week 8: Gaining ≥0 Letters212815
Week 12: Gaining ≥15 Letters273
Week 12: Gaining ≥10 Letters8167
Week 12: Gaining ≥5 Letters152311
Week 12: Gaining ≥0 Letters192915
Week 16: Gaining ≥15 Letters493
Week 16: Gaining ≥10 Letters10168
Week 16: Gaining ≥5 Letters162713
Week 16: Gaining ≥0 Letters212916
Week 20: Gaining ≥15 Letters4103
Week 20: Gaining ≥10 Letters10179
Week 20: Gaining ≥5 Letters162214
Week 20: Gaining ≥0 Letters202616
Week 24: Gaining ≥15 Letters484
Week 24: Gaining ≥10 Letters9169
Week 24: Gaining ≥5 Letters152212
Week 24: Gaining ≥0 Letters192715
Week 28: Gaining ≥15 Letters6125
Week 28: Gaining ≥10 Letters13159
Week 28: Gaining ≥5 Letters162411
Week 28: Gaining ≥0 Letters212716
Week 32: Gaining ≥15 Letters7116
Week 32: Gaining ≥10 Letters11189
Week 32: Gaining ≥5 Letters172711
Week 32: Gaining ≥0 Letters222815
Week 36: Gaining ≥15 Letters7116
Week 36: Gaining ≥10 Letters102010
Week 36: Gaining ≥5 Letters152412
Week 36: Gaining ≥0 Letters192515
Week 40: Gaining ≥15 Letters8115
Week 40: Gaining ≥10 Letters11188
Week 40: Gaining ≥5 Letters152410
Week 40: Gaining ≥0 Letters172713
Week 44: Gaining ≥15 Letters7136
Week 44: Gaining ≥10 Letters12159
Week 44: Gaining ≥5 Letters132611
Week 44: Gaining ≥0 Letters152713
Week 48: Gaining ≥15 Letters7106
Week 48: Gaining ≥10 Letters121710
Week 48: Gaining ≥5 Letters152011
Week 48: Gaining ≥0 Letters182612
Week 52: Gaining ≥15 Letters7136
Week 52: Gaining ≥10 Letters11179
Week 52: Gaining ≥5 Letters14239
Week 52: Gaining ≥0 Letters172613
SecondaryPercentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 74.2 (0.00 to 9.39)6.5 (0.80 to 12.11)6.3 (0.00 to 14.01)
Week 412.5 (3.85 to 21.15)12.9 (5.19 to 20.62)18.8 (6.24 to 31.26)
Week 812.5 (3.85 to 21.15)16.7 (7.95 to 25.39)40.0 (23.79 to 56.21)
Week 128.7 (1.17 to 16.23)23.3 (13.44 to 33.23)18.8 (6.24 to 31.26)
Week 1617.4 (7.26 to 27.52)30.0 (19.28 to 40.72)18.8 (6.24 to 31.26)
Week 2017.4 (7.26 to 27.52)33.3 (22.30 to 44.36)18.8 (6.24 to 31.26)
Week 2417.4 (7.26 to 27.52)26.7 (16.32 to 37.01)25.0 (11.13 to 38.87)
Week 2826.1 (14.35 to 37.82)40.0 (28.54 to 51.46)31.3 (16.40 to 46.10)
Week 3230.4 (18.14 to 42.73)36.7 (25.39 to 47.94)37.5 (21.99 to 53.01)
Week 3631.8 (19.09 to 44.54)37.9 (26.38 to 49.48)37.5 (21.99 to 53.01)
Week 4038.1 (24.51 to 51.68)39.3 (27.46 to 51.11)33.3 (17.73 to 48.93)
Week 4435.0 (21.33 to 48.67)44.8 (32.99 to 56.66)37.5 (21.99 to 53.01)
Week 4833.3 (20.15 to 46.52)35.7 (24.11 to 47.32)37.5 (21.99 to 53.01)
Week 5233.3 (20.15 to 46.52)46.4 (34.35 to 58.51)37.5 (21.99 to 53.01)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 4.76 · 80% CI -15.92 to 25.44The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 5.95 · 80% CI -13.62 to 25.53The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: -4.17 · 80% CI -24.52 to 16.19The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 8.93 · 80% CI -10.73 to 28.59The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryNumber and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Count of participants · Participants
Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 7: Not Losing ≥15 Letters243116
Day 7: Not Losing ≥10 Letters243116
Day 7: Not Losing ≥5 Letters212915
Day 7: Not Losing ≥0 Letters182410
Week 4: Not Losing ≥15 Letters243116
Week 4: Not Losing ≥10 Letters243116
Week 4: Not Losing ≥5 Letters233116
Week 4: Not Losing ≥0 Letters182913
Week 8: Not Losing ≥15 Letters233015
Week 8: Not Losing ≥10 Letters233015
Week 8: Not Losing ≥5 Letters222915
Week 8: Not Losing ≥0 Letters202813
Week 12: Not Losing ≥15 Letters232916
Week 12: Not Losing ≥10 Letters232916
Week 12: Not Losing ≥5 Letters232916
Week 12: Not Losing ≥0 Letters192814
Week 16: Not Losing ≥15 Letters232916
Week 16: Not Losing ≥10 Letters232916
Week 16: Not Losing ≥5 Letters222916
Week 16: Not Losing ≥0 Letters192916
Week 20: Not Losing ≥15 Letters232916
Week 20: Not Losing ≥10 Letters232916
Week 20: Not Losing ≥5 Letters222916
Week 20: Not Losing ≥0 Letters192414
Week 24: Not Losing ≥15 Letters233016
Week 24: Not Losing ≥10 Letters222916
Week 24: Not Losing ≥5 Letters222816
Week 24: Not Losing ≥0 Letters192714
Week 28: Not Losing ≥15 Letters232916
Week 28: Not Losing ≥10 Letters232816
Week 28: Not Losing ≥5 Letters212816
Week 28: Not Losing ≥0 Letters202716
Week 32: Not Losing ≥15 Letters232916
Week 32: Not Losing ≥10 Letters232816
Week 32: Not Losing ≥5 Letters222816
Week 32: Not Losing ≥0 Letters202813
Week 36: Not Losing ≥15 Letters212816
Week 36: Not Losing ≥10 Letters212816
Week 36: Not Losing ≥5 Letters202715
Week 36: Not Losing ≥0 Letters192514
Week 40: Not Losing ≥15 Letters202715
Week 40: Not Losing ≥10 Letters202715
Week 40: Not Losing ≥5 Letters192715
Week 40: Not Losing ≥0 Letters172512
Week 44: Not Losing ≥15 Letters202816
Week 44: Not Losing ≥10 Letters202816
Week 44: Not Losing ≥5 Letters172816
Week 44: Not Losing ≥0 Letters142712
Week 48: Not Losing ≥15 Letters212716
Week 48: Not Losing ≥10 Letters202716
Week 48: Not Losing ≥5 Letters192715
Week 48: Not Losing ≥0 Letters162511
Week 52: Not Losing ≥15 Letters212716
Week 52: Not Losing ≥10 Letters212716
Week 52: Not Losing ≥5 Letters202715
Week 52: Not Losing ≥0 Letters162611
SecondaryPercentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 7100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)
Week 4100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)
Week 895.8 (90.61 to 100.00)100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)
Week 12100.0 (100.00 to 100.00)96.7 (92.47 to 100.00)100.0 (100.00 to 100.00)
Week 16100.0 (100.00 to 100.00)96.7 (92.47 to 100.00)100.0 (100.00 to 100.00)
Week 20100.0 (100.00 to 100.00)96.7 (92.47 to 100.00)100.0 (100.00 to 100.00)
Week 24100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)100.0 (100.00 to 100.00)
Week 28100.0 (100.00 to 100.00)96.7 (92.47 to 100.00)100.0 (100.00 to 100.00)
Week 32100.0 (100.00 to 100.00)96.7 (92.47 to 100.00)100.0 (100.00 to 100.00)
Week 3695.5 (89.76 to 100.00)96.6 (92.21 to 100.00)100.0 (100.00 to 100.00)
Week 4095.2 (89.28 to 100.00)96.4 (91.93 to 100.00)100.0 (100.00 to 100.00)
Week 44100.0 (100.00 to 100.00)96.6 (92.21 to 100.00)100.0 (100.00 to 100.00)
Week 48100.0 (100.00 to 100.00)96.4 (91.93 to 100.00)100.0 (100.00 to 100.00)
Week 52100.0 (100.00 to 100.00)96.4 (91.93 to 100.00)100.0 (100.00 to 100.00)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: -4.76 · 80% CI -10.72 to 1.19The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: -3.57 · 80% CI -8.07 to 0.92The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 0The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: -3.57 · 80% CI -8.07 to 0.92The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline12.5 (3.85 to 21.15)22.6 (12.96 to 32.20)18.8 (6.24 to 31.26)
Day 720.8 (10.21 to 31.46)45.2 (33.71 to 56.62)18.8 (6.24 to 31.26)
Week 445.8 (32.80 to 58.87)51.6 (40.11 to 63.12)25.0 (11.13 to 38.87)
Week 841.7 (28.77 to 54.56)70.0 (59.28 to 80.72)20.0 (6.76 to 33.24)
Week 1243.5 (30.23 to 56.73)73.3 (62.99 to 83.68)31.3 (16.40 to 46.10)
Week 1652.2 (38.83 to 65.52)70.0 (59.28 to 80.72)43.8 (27.86 to 59.64)
Week 2047.8 (34.48 to 61.17)73.3 (62.99 to 83.68)50.0 (33.98 to 66.02)
Week 2456.5 (43.27 to 69.77)70.0 (59.28 to 80.72)37.5 (21.99 to 53.01)
Week 2856.5 (43.27 to 69.77)73.3 (62.99 to 83.68)37.5 (21.99 to 53.01)
Week 3260.9 (47.83 to 73.91)70.0 (59.28 to 80.72)43.8 (27.86 to 59.64)
Week 3659.1 (45.66 to 72.52)75.9 (65.68 to 86.05)43.8 (27.86 to 59.64)
Week 4061.9 (48.32 to 75.49)78.6 (68.63 to 88.51)40.0 (23.79 to 56.21)
Week 4450.0 (35.67 to 64.33)72.4 (61.78 to 83.05)37.5 (21.99 to 53.01)
Week 4857.1 (43.30 to 70.98)75.0 (64.51 to 85.49)37.5 (21.99 to 53.01)
Week 5257.1 (43.30 to 70.98)71.4 (60.49 to 82.37)37.5 (21.99 to 53.01)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 21.90 · 80% CI 0.76 to 43.05The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 38.57 · 80% CI 19.56 to 57.59The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 19.64 · 80% CI -1.14 to 40.43The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 33.93 · 80% CI 14.95 to 52.91The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline8.3 (1.10 to 15.56)3.2 (0.00 to 7.29)12.5 (1.90 to 23.10)
Day 74.2 (0.00 to 9.39)0 (0.00 to 0.00)0 (0.00 to 0.00)
Week 44.2 (0.00 to 9.39)3.2 (0.00 to 7.29)0 (0.00 to 0.00)
Week 88.3 (1.10 to 15.56)6.7 (0.83 to 12.50)0 (0.00 to 0.00)
Week 124.3 (0.00 to 9.80)6.7 (0.83 to 12.50)0 (0.00 to 0.00)
Week 164.3 (0.00 to 9.80)3.3 (0.00 to 7.53)0 (0.00 to 0.00)
Week 204.3 (0.00 to 9.80)6.7 (0.83 to 12.50)0 (0.00 to 0.00)
Week 244.3 (0.00 to 9.80)6.7 (0.83 to 12.50)0 (0.00 to 0.00)
Week 284.3 (0.00 to 9.80)3.3 (0.00 to 7.53)0 (0.00 to 0.00)
Week 324.3 (0.00 to 9.80)3.3 (0.00 to 7.53)0 (0.00 to 0.00)
Week 364.5 (0.00 to 10.24)3.4 (0.00 to 7.79)0 (0.00 to 0.00)
Week 400 (0.00 to 0.00)3.6 (0.00 to 8.07)0 (0.00 to 0.00)
Week 445.0 (0.00 to 11.25)3.4 (0.00 to 7.79)0 (0.00 to 0.00)
Week 484.8 (0.00 to 10.72)3.6 (0.00 to 8.07)0 (0.00 to 0.00)
Week 524.8 (0.00 to 10.72)3.6 (0.00 to 8.07)0 (0.00 to 0.00)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 0The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 3.57 · 80% CI -0.92 to 8.07The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 4.76 · 80% CI -1.19 to 10.72The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Difference in percentage of participants: 3.57 · 80% CI -0.92 to 8.07The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryMean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints

Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Least squares mean · microns (μm)
Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints
microns (μm)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 7-93.56 (-109.05 to -78.07)-94.31 (-107.78 to -80.83)-76.01 (-95.07 to -56.95)
Week 4-132.27 (-146.13 to -118.41)-130.11 (-142.37 to -117.85)-122.07 (-139.47 to -104.67)
Week 8-134.47 (-148.30 to -120.65)-136.15 (-148.42 to -123.89)-127.64 (-145.03 to -110.24)
Week 12-142.26 (-157.01 to -127.52)-139.63 (-152.66 to -126.59)-126.63 (-145.03 to -108.24)
Week 16-134.94 (-150.26 to -119.63)-137.81 (-151.37 to -124.25)-120.48 (-139.55 to -101.40)
Week 20-125.05 (-143.75 to -106.35)-125.35 (-141.86 to -108.84)-120.70 (-143.69 to -97.70)
Week 24-121.13 (-140.94 to -101.31)-108.66 (-126.14 to -91.17)-131.29 (-155.62 to -106.96)
Week 28-131.58 (-148.18 to -114.99)-116.76 (-131.41 to -102.12)-130.29 (-150.80 to -109.78)
Week 32-127.85 (-149.31 to -106.38)-123.44 (-142.37 to -104.51)-134.29 (-160.61 to -107.97)
Week 36-114.27 (-134.82 to -93.71)-114.97 (-133.02 to -96.92)-149.26 (-174.17 to -124.35)
Week 40-137.54 (-156.68 to -118.40)-123.31 (-140.20 to -106.42)-137.99 (-161.27 to -114.71)
Week 44-135.30 (-154.78 to -115.82)-110.26 (-127.23 to -93.30)-135.70 (-159.16 to -112.23)
Week 48-125.93 (-145.69 to -106.17)-121.67 (-139.07 to -104.26)-130.76 (-154.93 to -106.58)
Week 52-140.95 (-157.06 to -124.85)-134.99 (-149.21 to -120.76)-136.10 (-155.98 to -116.23)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 0.45 · 80% CI -29.81 to 30.71The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 14.68 · 80% CI -14.29 to 43.65The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): -4.85 · 80% CI -30.57 to 20.87The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 1.12 · 80% CI -23.57 to 25.80The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryMean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints

Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Least squares mean · microns (μm)
Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints
microns (μm)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Day 7-88.87 (-100.40 to -77.34)-84.23 (-94.35 to -74.11)-80.08 (-94.15 to -66.01)
Week 4-127.20 (-139.69 to -114.72)-123.10 (-134.18 to -112.02)-111.58 (-126.99 to -96.17)
Week 8-132.03 (-145.40 to -118.67)-131.25 (-143.13 to -119.37)-117.04 (-133.54 to -100.53)
Week 12-134.70 (-148.96 to -120.44)-132.87 (-145.53 to -120.20)-122.39 (-139.93 to -104.85)
Week 16-132.96 (-147.69 to -118.23)-132.50 (-145.58 to -119.42)-122.70 (-140.81 to -104.60)
Week 20-114.97 (-131.83 to -98.12)-118.89 (-133.77 to -104.00)-120.77 (-141.28 to -100.25)
Week 24-101.62 (-119.69 to -83.54)-99.35 (-115.29 to -83.42)-121.33 (-143.26 to -99.40)
Week 28-129.68 (-144.40 to -114.95)-109.89 (-122.91 to -96.87)-127.95 (-145.93 to -109.98)
Week 32-121.10 (-139.50 to -102.71)-116.35 (-132.57 to -100.14)-127.20 (-149.56 to -104.85)
Week 36-101.98 (-121.60 to -82.36)-102.69 (-119.96 to -85.42)-118.89 (-142.63 to -95.15)
Week 40-138.55 (-154.04 to -123.05)-121.34 (-135.07 to -107.62)-126.32 (-145.20 to -107.44)
Week 44-130.50 (-146.19 to -114.81)-103.31 (-117.04 to -89.57)-124.89 (-143.71 to -106.08)
Week 48-126.45 (-145.58 to -107.33)-102.30 (-119.14 to -85.47)-123.89 (-147.01 to -100.77)
Week 52-138.53 (-152.42 to -124.65)-122.53 (-134.81 to -110.25)-129.89 (-146.74 to -113.04)
Statistical analysis
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): -12.23 · 80% CI -36.60 to 12.15The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 4.98 · 80% CI -18.50 to 28.45The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q12W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): -8.64 · 80% CI -30.42 to 13.14The difference was calculated as Faricimab Q12W arm minus Ranibizumab Q4W arm.
  • 6 mg Faricimab Q16W vs 0.5 mg Ranibizumab Q4W · Mean difference (net): 7.36 · 80% CI -13.65 to 28.37The difference was calculated as Faricimab Q16W arm minus Ranibizumab Q4W arm.
SecondaryPercentage of Participants With No Intraretinal Fluid at Specified Timepoints

The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With No Intraretinal Fluid at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline4.2 (0.00 to 9.39)29.0 (18.58 to 39.48)18.8 (6.24 to 31.26)
Day 721.7 (10.72 to 32.76)38.7 (27.50 to 49.92)25.0 (11.13 to 38.87)
Week 429.2 (17.28 to 41.06)48.4 (36.88 to 59.89)50.0 (33.98 to 66.02)
Week 833.3 (21.00 to 45.67)46.7 (34.99 to 58.34)26.7 (12.03 to 41.30)
Week 1239.1 (26.09 to 52.17)43.3 (31.74 to 54.93)37.5 (21.99 to 53.01)
Week 1647.8 (34.48 to 61.17)50.0 (38.30 to 61.70)37.5 (21.99 to 53.01)
Week 2043.5 (30.23 to 56.73)53.3 (41.66 to 65.01)18.8 (6.24 to 31.26)
Week 2430.4 (18.14 to 42.73)50.0 (38.30 to 61.70)31.3 (16.40 to 46.10)
Week 2826.1 (14.35 to 37.82)53.3 (41.66 to 65.01)31.3 (16.40 to 46.10)
Week 3226.1 (14.35 to 37.82)50.0 (38.30 to 61.70)31.3 (16.40 to 46.10)
Week 3631.8 (19.09 to 44.54)44.8 (32.99 to 56.66)37.5 (21.99 to 53.01)
Week 4038.1 (24.51 to 51.68)57.1 (45.16 to 69.13)33.3 (17.73 to 48.93)
Week 4455.0 (40.74 to 69.26)48.3 (36.38 to 60.17)43.8 (27.86 to 59.64)
Week 4838.1 (24.51 to 51.68)53.6 (41.49 to 65.65)62.5 (46.99 to 78.01)
Week 5238.1 (24.51 to 51.68)35.7 (24.11 to 47.32)62.5 (46.99 to 78.01)
SecondaryPercentage of Participants With No Subretinal Fluid at Specified Timepoints

The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With No Subretinal Fluid at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline20.8 (10.21 to 31.46)12.9 (5.19 to 20.62)25.0 (11.13 to 38.87)
Day 739.1 (26.09 to 52.17)29.0 (18.58 to 39.48)31.3 (16.40 to 46.10)
Week 470.8 (58.94 to 82.72)77.4 (67.80 to 87.04)62.5 (46.99 to 78.01)
Week 883.3 (73.58 to 93.08)86.7 (78.71 to 94.62)80.0 (66.76 to 93.24)
Week 1291.3 (83.77 to 98.83)90.0 (82.98 to 97.02)75.0 (61.13 to 88.87)
Week 1687.0 (77.96 to 95.96)96.7 (92.47 to 100.00)75.0 (61.13 to 88.87)
Week 2069.6 (57.27 to 81.86)70.0 (59.28 to 80.72)87.5 (76.90 to 98.10)
Week 2465.2 (52.49 to 77.94)66.7 (55.64 to 77.70)75.0 (61.13 to 88.87)
Week 2891.3 (83.77 to 98.83)70.0 (59.28 to 80.72)75.0 (61.13 to 88.87)
Week 3269.6 (57.27 to 81.86)80.0 (70.64 to 89.36)68.8 (53.90 to 83.60)
Week 3668.2 (55.46 to 80.91)72.4 (61.78 to 83.05)81.3 (68.74 to 93.76)
Week 4081.0 (69.97 to 91.93)89.3 (81.79 to 96.78)86.7 (75.42 to 97.91)
Week 4480.0 (68.54 to 91.46)75.9 (65.68 to 86.05)81.3 (68.74 to 93.76)
Week 4871.4 (58.79 to 84.06)64.3 (52.68 to 75.89)87.5 (76.90 to 98.10)
Week 5281.0 (69.97 to 91.93)89.3 (81.79 to 96.78)87.5 (76.90 to 98.10)
SecondaryPercentage of Participants With No Cysts at Specified Timepoints

The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With No Cysts at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline33.3 (21.00 to 45.67)48.4 (36.88 to 59.89)37.5 (21.99 to 53.01)
Day 765.2 (52.49 to 77.94)83.9 (75.41 to 92.34)75.0 (61.13 to 88.87)
Week 487.5 (78.85 to 96.15)87.1 (79.38 to 94.81)87.5 (76.90 to 98.10)
Week 883.3 (73.58 to 93.08)83.3 (74.61 to 92.05)86.7 (75.42 to 97.91)
Week 1291.3 (83.77 to 98.83)83.3 (74.61 to 92.05)68.8 (53.90 to 83.60)
Week 1691.3 (83.77 to 98.83)83.3 (74.61 to 92.05)75.0 (61.13 to 88.87)
Week 2091.3 (83.77 to 98.83)80.0 (70.64 to 89.36)68.8 (53.90 to 83.60)
Week 2473.9 (62.18 to 85.65)76.7 (66.77 to 86.56)68.8 (53.90 to 83.60)
Week 2895.7 (90.20 to 100.00)70.0 (59.28 to 80.72)68.8 (53.90 to 83.60)
Week 3282.6 (72.48 to 92.74)76.7 (66.77 to 86.56)75.0 (61.13 to 88.87)
Week 3677.3 (65.82 to 88.72)79.3 (69.67 to 88.95)68.8 (53.90 to 83.60)
Week 4085.7 (75.93 to 95.50)78.6 (68.63 to 88.51)80.0 (66.76 to 93.24)
Week 44100.0 (100.00 to 100.00)72.4 (61.78 to 83.05)87.5 (76.90 to 98.10)
Week 4895.2 (89.28 to 100.00)85.7 (77.24 to 94.19)87.5 (76.90 to 98.10)
Week 52100.0 (100.00 to 100.00)78.6 (68.63 to 88.51)87.5 (76.90 to 98.10)
SecondaryPercentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints

The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.

Time frame:
Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints
Percentage of participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline8.3 (1.10 to 15.56)29.0 (18.58 to 39.48)12.5 (1.90 to 23.10)
Day 713.0 (4.04 to 22.04)29.0 (18.58 to 39.48)12.5 (1.90 to 23.10)
Week 48.3 (1.10 to 15.56)22.6 (12.96 to 32.20)12.5 (1.90 to 23.10)
Week 88.3 (1.10 to 15.56)23.3 (13.44 to 33.23)13.3 (2.09 to 24.58)
Week 128.7 (1.17 to 16.23)26.7 (16.32 to 37.01)12.5 (1.90 to 23.10)
Week 168.7 (1.17 to 16.23)23.3 (13.44 to 33.23)12.5 (1.90 to 23.10)
Week 2013.0 (4.04 to 22.04)23.3 (13.44 to 33.23)12.5 (1.90 to 23.10)
Week 2413.0 (4.04 to 22.04)23.3 (13.44 to 33.23)12.5 (1.90 to 23.10)
Week 2813.0 (4.04 to 22.04)20.0 (10.64 to 29.36)12.5 (1.90 to 23.10)
Week 3213.0 (4.04 to 22.04)23.3 (13.44 to 33.23)12.5 (1.90 to 23.10)
Week 364.5 (0.00 to 10.24)20.7 (11.05 to 30.33)12.5 (1.90 to 23.10)
Week 404.8 (0.00 to 10.72)21.4 (11.49 to 31.37)13.3 (2.09 to 24.58)
Week 445.0 (0.00 to 11.25)17.2 (8.25 to 26.23)12.5 (1.90 to 23.10)
Week 489.5 (1.31 to 17.73)17.9 (8.58 to 27.13)12.5 (1.90 to 23.10)
Week 5214.3 (4.50 to 24.07)14.3 (5.81 to 22.76)12.5 (1.90 to 23.10)
SecondaryMean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52

The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Baseline, Week 40, Week 52
Reported as:
Mean · millimetres squared (mm^2)
Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52
millimetres squared (mm^2)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline (BL): Absolute Value7.1 ± 3.95.9 ± 3.87.3 ± 2.9
Change from BL at Week 40-4.7 ± 4.3-3.9 ± 3.7-4.6 ± 3.5
Change from BL at Week 52-5.4 ± 4.0-4.2 ± 3.4-4.5 ± 3.2
SecondaryMean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52

The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Baseline, Week 40, Week 52
Reported as:
Mean · millimetres squared (mm^2)
Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52
millimetres squared (mm^2)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline (BL): Absolute Value7.0 ± 3.85.8 ± 3.67.1 ± 3.0
Change from BL at Week 40-5.0 ± 4.2-4.0 ± 4.0-4.7 ± 3.4
Change from BL at Week 52-5.6 ± 4.0-4.3 ± 3.7-4.8 ± 3.2
SecondaryMean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52

The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Baseline, Week 40, Week 52
Reported as:
Mean · millimetres squared (mm^2)
Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52
millimetres squared (mm^2)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Baseline (BL): Absolute Value7.0 ± 3.86.1 ± 3.47.6 ± 2.9
Change from BL at Week 40-5.0 ± 4.2-4.3 ± 3.9-5.3 ± 3.7
Change from BL at Week 52-5.6 ± 4.0-4.6 ± 3.5-5.3 ± 3.5
SecondaryChange From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline

Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA).

Time frame:
Predose at Baseline (Day 1), Weeks 16, 24, 28, 44, and 52
Reported as:
Count of participants · Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline
Participants6 mg Faricimab Q12W6 mg Faricimab Q16W
ADA Negative to ADA Negative2125
ADA Negative to ADA Positive14
Missing to ADA Negative01
Missing to ADA Positive10
No Post-Baseline ADA Assessment11
SecondarySafety Summary: Number and Percentage of Participants With at Least One Adverse Event

This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.

Time frame:
From Baseline until 28 days after the last dose of study drug (up to 52 weeks)
Reported as:
Count of participants · Participants
Safety Summary: Number and Percentage of Participants With at Least One Adverse Event
Participants6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Any Adverse Event (AE)182313
Serious AE (SAE)430
SAE Leading to Withdrawal from Treatment000
SAE Leading to Dose Modification/Interruption100
Serious Ocular AE000
Serious Non-Ocular AE430
AE Leading to Withdrawal from Treatment000
AE Leading to Dose Modification/Interruption200
Ocular AE in the Study Eye9118
Ocular AE in the Fellow Eye656
Non-Ocular AE14209

Adverse events

Collected over From Baseline until 28 days after the last dose of study drug (up to 52 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
6 mg Faricimab Q12W1/24 (4.2%)4/24 (16.7%)18/24 (75%)
6 mg Faricimab Q16W2/31 (6.5%)3/31 (9.7%)22/31 (71%)
0.5 mg Ranibizumab Q4W0/16 (0%)0/16 (0%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
Event6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Acute left ventricular failureCardiac disorders1/240/310/16
Coronary artery diseaseCardiac disorders1/240/310/16
VertigoEar and labyrinth disorders1/240/310/16
FallInjury, poisoning and procedural complications1/240/310/16
HeadacheNervous system disorders1/240/310/16
Ischaemic strokeNervous system disorders1/240/310/16
Mental status changesPsychiatric disorders1/240/310/16
Atrial fibrillationCardiac disorders0/241/310/16
SepsisInfections and infestations0/241/310/16
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/241/310/16
Most frequent other events
Showing 10 of 100
Most frequent other events
Event6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4W
Conjunctival haemorrhageEye disorders5/244/314/16
NasopharyngitisInfections and infestations4/242/311/16
FallInjury, poisoning and procedural complications0/245/311/16
Neovascular age-related macular degenerationEye disorders3/240/312/16
Eye painEye disorders2/240/312/16
Retinal haemorrhageEye disorders2/240/312/16
CataractEye disorders2/241/310/16
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/240/310/16
MaculopathyEye disorders0/242/310/16
Urinary tract infectionInfections and infestations1/242/311/16

Baseline characteristics

The efficacy population includes randomized participants grouped according to their assigned treatment. A total of 76 patients were randomized in the study, but 5 participants in total (all randomized to the 6 mg Faricimab Q12W Arm) were excluded from the analysis populations because of Good Clinical Practice (GCP) violations at a single site.

Age, Continuous
Age, Continuous(Years)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Mean80.3 ± 7.2377.7 ± 8.3877.3 ± 10.2978.5 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Female13181041
Male1113630
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Hispanic or Latino1001
Not Hispanic or Latino23311670
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Asian0101
Black or African American1001
White23301669
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline(ETDRS Letters)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Mean57.8 ± 10.4660.4 ± 10.8055.3 ± 12.0858.4 ± 11.02
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline(Participants)6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Classic and Occult CNV0224
Classic CNV99624
Occult CNV1520843
Central Foveal Thickness in the Study Eye at Baseline
Central Foveal Thickness in the Study Eye at Baseline(microns (μm))6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Mean290.8 ± 118.61280.8 ± 98.95375.6 ± 159.41305.6 ± 125.42
Central Subfield Thickness in the Study Eye at Baseline
Central Subfield Thickness in the Study Eye at Baseline(microns (μm))6 mg Faricimab Q12W6 mg Faricimab Q16W0.5 mg Ranibizumab Q4WTotal
Mean417.9 ± 84.28382.2 ± 80.87443.1 ± 125.00408.0 ± 95.36
08

Study locations

25 sites
  • Retinal Consultants of Arizona
    Phoenix, Arizona 85053, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Retina Consultants of Southern Colorado PC; Clinical Research Department
    Colorado Springs, Colorado 80909-1183, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Vitreous Assoc of FL
    Saint Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Vitreo Retinal Surgery
    Minneapolis, Minnesota 55435, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Eye Associates of New Mexico
    Albuquerque, New Mexico 87109, United States
  • Vitreoretinal Consultants
    Great Neck, New York 11021, United States
  • Oregon Retina, LLP
    Eugene, Oregon 97401, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Arlington, Texas 76012, United States
  • Retina Research Center
    Austin, Texas 78750, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2020 Sep 1;138(9):964-972. doi: 10.1001/jamaophthalmol.2020.2699. Erratum In: JAMA Ophthalmol. 2020 Sep 1;138(9):1006. doi: 10.1001/jamaophthalmol.2020.3537. PubMed 32729897 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jan 2018, 11 months.

Results were first posted in Jan 2021, 2 years 11 months after primary completion. A results delay was requested in Jan 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 1, 2017
StartActual
Jan 27, 2017
Primary completionActual
Jan 11, 2018
CompletionActual
Mar 29, 2018
Results delay requested
Jan 11, 2019
Results first posted
Jan 5, 2021
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03038880
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 1, 2017
Start date
Jan 27, 2017
Primary completion
Jan 11, 2018
Completion
Mar 29, 2018
Results posted
Jan 5, 2021
Last update
Jan 5, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion